Triple
T17093457
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | NewLink Genetics |
E414780
|
entity |
| Predicate | hasTechnology |
P1485
|
FINISHED |
| Object |
HyperAcute cellular immunotherapy platform
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
|
E1249866
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: HyperAcute cellular immunotherapy platform | Statement: [NewLink Genetics, hasTechnology, HyperAcute cellular immunotherapy platform]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: HyperAcute cellular immunotherapy platform Context triple: [NewLink Genetics, hasTechnology, HyperAcute cellular immunotherapy platform]
-
A.
VelocImmune technology
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
C.
exagamglogene autotemcel
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
D.
Research Center for Immunotherapy
The Research Center for Immunotherapy is a specialized institute at Johannes Gutenberg University Mainz dedicated to advancing understanding and development of immune-based treatments for diseases such as cancer and autoimmune disorders.
-
E.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: HyperAcute cellular immunotherapy platform Triple: [NewLink Genetics, hasTechnology, HyperAcute cellular immunotherapy platform]
Generated description
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: HyperAcute cellular immunotherapy platform Target entity description: HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
-
A.
VelocImmune technology
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
C.
exagamglogene autotemcel
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
D.
Research Center for Immunotherapy
The Research Center for Immunotherapy is a specialized institute at Johannes Gutenberg University Mainz dedicated to advancing understanding and development of immune-based treatments for diseases such as cancer and autoimmune disorders.
-
E.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d886cfc8e88190b05ba466edd35591 |
completed | April 10, 2026, 5:12 a.m. |
| NER | Named-entity recognition | batch_69e3dbfb89348190942984037bd3bd2e |
completed | April 18, 2026, 7:31 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a012eec0d5c8190806e756aae848ba2 |
completed | May 11, 2026, 1:20 a.m. |
| NEDg | Description generation | batch_6a012f7f8b148190914b0d7cfb2d5c5c |
completed | May 11, 2026, 1:23 a.m. |
| NED2 | Entity disambiguation (via description) | batch_6a012ffb67d4819099ec8d668cb590c9 |
completed | May 11, 2026, 1:25 a.m. |
Created at: April 10, 2026, 5:35 a.m.